Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

Figures & data

Table I. Patient demographics and disease characteristics of PsO, PsA and PsO/PsA patients who initiated etanercept or adalimumab at baseline.

	Patients initiating etanercept (n = 2,534)			Patients initiating adalimumab (n = 1,919)
	PsO (n = 1,609)	PsA (n = 679)	PsO/PsA (n = 246)	PsO (n = 1,166)	PsA (n = 518)	PsO/PsA (n = 235)
Age, mean years (SD)	45.5 (12.7)	48.2 (11.0)	47.9 (12.3)	45.8 (12.1)	47.6 (10.8)	47.6 (11.8)
Sex, n women (%)	690 (42.9)	302 (44.5)	103 (41.9)	525 (45.0)	248 (47.9)	120 (51.1)
Geographic region, n (%)  Northeast  North Central  South  West  Unknown	161 (10.0) 456 (28.3) 708 (44.0) 277 (17.2) 7 (0.4)	92 (13.5) 147 (21.6) 291 (42.9) 148 (21.8) 1 (0.1)	32 (13.0) 60 (24.4) 100 (40.7) 51 (20.7) 3 (1.2)	73 (6.3) 324 (27.8) 582 (49.9) 185 (15.9) 2 (0.2)	77 (14.9) 111 (21.4) 241 (46.5) 89 (17.2) 0	20 (8.5) 58 (24.7) 126 (53.6) 30 (12.8) 1 (0.4)
Provider Specialty  Rheumatologist  Dermatologist  Other  Missing	16 (1.0) 1262 (78.4) 291 (18.1) 40 (2.5)	396 (58.3) 15 (2.2) 247 (36.4) 21 (3.1)	86 (35.0) 70 (28.5) 80 (32.5) 10 (4.1)	15 (1.3) 927 (79.5) 202 (17.3) 22 (1.9)	301 (58.1) 14 (2.7) 192 (37.1) 11 (2.1)	86 (36.6) 59 (25.1) 74 (31.5) 16 (6.8)
Charlson-Deyo Comorbidity Index, mean score (SD)	0.20 (0.57)	0.26 (0.73)	0.22 (0.53)	0.19 (0.60)	0.19 (0.55)	0.24 (0.62)
Comorbid conditions, n (%)  Hypertensive disease  Ischaemic heart disease*  Conduction & rhythm disorders  Heart failure  Other heart disease  Cerebrovascular disease  Peripheral arterial disease  Venous disease  Other CV (non-heart) disease  Diabetes  Emphysema	244 (15.2) 55 (3.4) 26 (1.6) 7 (0.4) 28 (1.7) 15 (0.9) 13 (0.8) 35 (2.2) 13 (0.8) 155 (9.6) 0	117 (17.2) 28 (4.1) 28 (4.1) 5 (0.7) 12 (1.8) 8 (1.2) 7 (1.0) 13 (1.9) 9 (1.3) 62 (9.1) 0	46 (18.7) 38 (15.4) 5 (2.0) 1 (0.4) 7 (2.8) 0 0 7 (2.8) 4 (1.6) 26 (10.6) 1 (0.4)	191 (16.4) 16 (1.4) 32 (2.7) 7 (0.6) 26 (2.2) 10 (0.9) 7 (0.6) 24 (2.1) 13 (1.1) 106 (9.1) 4 (0.3)	77 (14.9) 5 (1.0) 12 (2.3) 5 (1.0) 10 (1.9) 5 (1.0) 5 (1.0) 9 (1.7) 6 (1.2) 47 (9.1) 0	41 (17.4) 26 (11.1) 10 (4.3) 1 (0.4) 6 (2.6) 3 (1.3) 3 (1.3) 8 (3.4) 2 (0.9) 24 (10.2) 0
Methotrexate use at baseline, n (%)	167 (10.4)	250 (36.8)	77 (31.3)	168 (14.4)	240 (46.3)	85 (36.2)

*Coronary arterial disease.

PsO = Psoriasis; PsA = Psoriatic arthritis; PsO/PsA = Both psoriasis and psoriatic arthritis; CV = Cardiovascular.

Table II. Treatment patterns in PsO, PsA and PsO/PsA patients.

	Patients initiating etanercept (n = 2,534)			Patients initiating adalimumab (n = 1,919)
	PsO (n = 1,609)	PsA (n = 679)	PsO/PsA (n = 246)	PsO (n = 1,166)	PsA (n = 518)	PsO/PsA (n = 235)
Initial dose of index therapy, n (%)  <50 mg weekly  50 mg weekly  51–99 mg weekly  100 mg weekly  40 mg EOW  >40 mg EOW to <40 mg weekly  40 mg weekly*  >40 mg weekly	33 (2.1) 417 (25.9) 253 (15.7) 906 (56.3)	24 (3.5) 598 (88.1) 16 (2.4) 41 (6.0)	7 (2.8) 162 (65.9) 16 (6.5) 61 (24.8)	311 (26.7) 103 (8.8) 715 (61.3) 37 (3.2)	468 (90.3) 7 (1.4) 40 (7.7) 3 (0.6)	157 (66.8) 7 (3.0) 68 (28.9) 3 (1.3)
Pauses per patient^†, mean no. (SD)	2.1 (1.7)^¶	2.0 (1.7)	2.1 (1.8)	1.9 (1.5)	1.8 (1.7)	1.9 (1.7)
Length of pause, mean days (SD)	19.3 (28.5)^¶	15.4 (22.9)	15.8 (21.8)	14.9 (24.2)	14.0 (21.5)	13.3 (20.5)
Longest pause, mean days (SD)	43.2 (43.7)^¶	34.2 (35.6)	34.2 (33.3)	34.7 (39.0)	30.4 (34.0)	29.0 (33.2)
Patients persistent on index medication for 12 months, n (%)	746 (46.4)	412 (60.7)	143 (58.1)	662 (56.8)^¶	328 (63.3)	140 (59.6)
Patients with 60-day gap^‡, n (%)	863 (53.6)^¶	267 (39.3)	103 (41.9)	504 (43.2)	190 (36.7)	95 (40.4)
Time to switch, mean days (SD)	199.9 (78.4)^||	191.6 (79.4)^§	189.7 (73.3)	193.2 (81.2)	178.9 (80.8)	179.3 (77.3)
Total time on treatment on index medication, mean days (SD)	305.0 (107.0)	325.2 (99.8)	321.4 (104.1)	318.2 (105.2)^¶	323.6 (104.0)	311.4 (110.3)
Total treatment on switch medication, mean days (SD)	321.0 (97.8)	337.5 (91.5)	339.3 (92.7)	327.7 (99.3)	338.7 (92.1)	322.5 (104.1)

*May be 80 mg loading dose followed by 40 mg every other week.

^†Pause in therapy of 7–59 days.

^‡Gap ≥60 days in index therapy.

^¶ p < 0.001.

^§ p < 0.01.

^|| p < 0.05.

PsO = Psoriasis; PsA = Psoriatic arthritis; PsO/PsA = Both psoriasis and psoriatic arthritis.